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Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases 
with  a  high  fatality  rate.    The  most  important  risk  factors  include  neutropenia  or  functional 
neutropenia, diabetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, 
illicit intravenous drug (ID) use, neonatal prematurity, malnourishment, and maybe a previous 
exposure  to  antifungal  agents  with  no  activity  against  zygomycetes,  such  as  vo
echinocandins.
A high index of suspicion is crucial for the diagnosis, as prompt and appropriate management can 
considerably reduce morbidity and mortality. Suspicion index can be increased through recognition 
of  the  differential  patterns  of
immunocompromised patients, mucormycosis
the underlying condition: mostly as rhino
infection in patients with malignancy or solid organ transplantation, disseminated infection in iron 
overloaded or deferoxamine treated patients, cerebral 
gastrointestinal in premature infants or malnourishment, and cutaneou
immunocompetent individuals with trauma or burns.
Treating a patient’s underlying medical condition and reducing immunosuppression are essential 
to therapy. Rapid correction of metabolic abnormalities is mandatory in cases suc
diabetes,  and  corticosteroids  or  other  immunosuppressive  drugs  should  be  discontinued  where 
feasible.  AmphotericinB  or  its  newer  and  less  toxic  lipid  formulations  are  the  drugs  of  choice 
regarding  antifungal  chemotherapy,  while  extensive 
infected  and  necrotic  tissue.  A  high  number  of  cases  could  be  prevented  through  measures 
including diabetes control programmes and proper pre
Introduction: The  term  ‘Zygomycosis’  refers  to  a 
group of rare infections caused by hyaline filamentous 
fungi belonging to the class of Zygomycetes. This class 
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Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases 
with  a  high  fatality  rate.    The  most  important  risk  factors  include  neutropenia  or  functional 
abetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, 
illicit intravenous drug (ID) use, neonatal prematurity, malnourishment, and maybe a previous 
exposure  to  antifungal  agents  with  no  activity  against  zygomycetes,  such  as  vo
A high index of suspicion is crucial for the diagnosis, as prompt and appropriate management can 
considerably reduce morbidity and mortality. Suspicion index can be increased through recognition 
of  the  differential  patterns  of clinical  presentation.  In  the  non
mucormycosis can manifest in various clinical forms, depending on 
the underlying condition: mostly as rhino-orbital or rhino-cerebral in diabetes patients, pulmonary 
n patients with malignancy or solid organ transplantation, disseminated infection in iron 
overloaded or deferoxamine treated patients, cerebral - with no sinus involvement 
gastrointestinal in premature infants or malnourishment, and cutaneous after direct inoculation in 
immunocompetent individuals with trauma or burns.
Treating a patient’s underlying medical condition and reducing immunosuppression are essential 
to therapy. Rapid correction of metabolic abnormalities is mandatory in cases suc
diabetes,  and  corticosteroids  or  other  immunosuppressive  drugs  should  be  discontinued  where 
feasible.  AmphotericinB  or  its  newer  and  less  toxic  lipid  formulations  are  the  drugs  of  choice 
regarding  antifungal  chemotherapy,  while  extensive surgical  debridement is  essential  to  reduce 
infected  and  necrotic  tissue.  A  high  number  of  cases  could  be  prevented  through  measures 
including diabetes control programmes and proper pre- and post-surgical hygiene. 
The  term  ‘Zygomycosis’  refers  to  a 
group of rare infections caused by hyaline filamentous 
fungi belonging to the class of Zygomycetes. This class 
is  subdivided  in  two  orders,  Mucorales  and 
Entomophthorales, both involved in human disease.
Mucorales are saprobiotic organisms ubiquitous in 
nature;  some  members  of  this  order  are  weak  plant
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Haematological Patients
National and Kapodistrian University of Athens, "ΑΤΤΙΚΟΝ" 
cle  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
which permits unrestricted use, distribution, and reproduction in any medium,
Zygomycoses caused by fungi of the mucorales order (mucormycoses) are emerging fungal diseases 
with  a  high  fatality  rate.    The  most  important  risk  factors  include  neutropenia  or  functional 
abetic ketoacidosis, iron overload, major trauma, prolonged use of corticosteroids, 
illicit intravenous drug (ID) use, neonatal prematurity, malnourishment, and maybe a previous 
exposure  to  antifungal  agents  with  no  activity  against  zygomycetes,  such  as  voriconazole  and 
A high index of suspicion is crucial for the diagnosis, as prompt and appropriate management can 
considerably reduce morbidity and mortality. Suspicion index can be increased through recognition 
clinical  presentation.  In  the  non- haematological 
can manifest in various clinical forms, depending on 
cerebral in diabetes patients, pulmonary 
n patients with malignancy or solid organ transplantation, disseminated infection in iron 
with no sinus involvement - in ID users, 
s after direct inoculation in 
Treating a patient’s underlying medical condition and reducing immunosuppression are essential 
to therapy. Rapid correction of metabolic abnormalities is mandatory in cases such as uncontrolled 
diabetes,  and  corticosteroids  or  other  immunosuppressive  drugs  should  be  discontinued  where 
feasible.  AmphotericinB  or  its  newer  and  less  toxic  lipid  formulations  are  the  drugs  of  choice 
surgical  debridement is  essential  to  reduce 
infected  and  necrotic  tissue.  A  high  number  of  cases  could  be  prevented  through  measures 
surgical hygiene. 
is  subdivided  in  two  orders,  Mucorales  and 
omophthorales, both involved in human disease.
1
Mucorales are saprobiotic organisms ubiquitous in 
nature;  some  members  of  this  order  are  weak  plantMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1.  Predisposing conditions for mucormycosis, pathogenetic mechanisms and clinical presentation.
Predisposing conditions for mucormycosis  Pathogenetic Mechanism Clinical presentation forms
(in order of frequency)
Haematological malignancies Haematopoietic 
stem cell transplantation (HSCT)
Prolonged neutropenia  1. Pulmonary, Sinus, 2. Cutaneous, 3. Sino-
orbital
Diabetic ketoacidosis
Uncontrolled diabetes mellitus
Impairment of neutrophil activation 
(functional neutropenia)/Fe usage by 
Zygomycetes for growth
1. Rhinocerebral , 2. Pulmonary, 
3. Sino-orbital,  4.Cutaneous
Prolonged  treatment with corticosteroids
Autoimmune disease
Defects in macrophages and 
neutrophils, cortico- steroid induced 
diabetes, hypocomplementemia
1. Disseminated, 2. Renal, 
3. Cutaneous, 4. Rhinocerebral, 
5. Gastrointestinal
Solid organ transplantation (SOT)/graft 
versus host disease (GVHD)
Cellular Immune suppression, 
Corticosteroid induced diabetes 
1. Pulmonary, 2. Sinus, 
3. Cutaneous , 4. Rhinocerebral, 
5. Disseminated
HIV infection/Intravenous illicit drug use Injection of spores contained in drugs 1. Cerebral, 2. Cutaneous, 3. Renal, 3. Heart, 
4. Rhinocerebral, 
5. Disseminated
Iron overload,
Iron/aluminium chelation therapy with 
deferoxamine (DFO)
Fe usage by Zygomycetes for growth
Fe-DFO action as siderophore
1. Disseminated, 2. Pulmonary, 
3. Rhinocerebral, 4. Cerebral, 
5. Cutaneous, 6. Gastrointestinal
Skin or soft tissue breakdown
burn/trauma/surgical wound/insect bite
Direct  cutaneous inoculation with high  
number of spores
1. Cutaneous, 2. Pulmonary, 
3. Sino-orbital, 4. Rhinocerebral, 
5. Gastrointestinal.
Prolonged use of broad spectrum antifungal 
agents (voriconazole, itraconazole and 
caspofungin).
Breakthrough infection due to 
resistance in these agents
Sino-pulmonary
Miscellaneous
    Neonatal prematurity
    Malnourishment
    Prolonged use of broad-spectrum 
antimicrobial agents
Ingestion of spores
Ingestion of spores
Replacement of normal bacterial biota
1. Cutaneous, 2. Gastrointestinal,  3.
Pulmonary, 4. Sino-orbital, 
5. Rhinocerebral
parasites  or  plant  pathogens  and  opportunistic 
pathogens  for  man.
2 The  vast  majority  of  human 
zygomycotic  disease  is  caused  by  genera  of  the 
Mucorales order, therefore, the term ‘mucormycosis’ is 
used interchangeably with the term ‘zygomycosis’ (the 
term ‘phycomycosis’ has also been used in the past). 
The most common genera confirmed in human disease 
are: Rhizopus, Mucor, Lichtheimia (formerly known as
Absidia corymbifera or  Mycocladus),  Rhizomucor, 
Apophysomyces, Saksenaea, and Cunninghamella.
1
For  Mucorales  the  portals  of  entry  in  the  human 
body  are  the  respiratory  tract through  inhalation  of 
fungal  spores,  the  skin  and  less  frequently  the  gut. 
They grow rapidly and produce wide hyaline, aseptate 
or poorly septated ribbon-like hyphae in tissues. They 
invade  blood  vessels  and  cause  thrombosis  and 
necrosis of the infected tissues. Disease in humans is 
limited  to  severely  immunocompromised  individuals, 
those with diabetic ketoacidosis, or those with burns or 
trauma.  Infection  usually  progresses  rapidly  and  the 
case  fatality  rate  is  very  high.  Depending  on  the 
underlying condition and the portal of entry they can 
cause  rhinocerebral,  pulmonary,  cutaneous, 
gastrointestinal or even disseminated infection.
1
Human  infections  caused  by  Entomophthorales, 
which  are  mainly  insect  pathogens,  constitute  a 
completely  different  clinical  entity 
(entomopfthoramycoses).  Genera  involved  in  human 
disease are Conidiobolus and Basidiobolus. They affect 
mainly immunocompetent individuals, are prevalent in 
the tropics and do not disseminate.
3 In recent years the 
geographic  distribution  of  basidiobolomycosis 
expanded and is reported also in immunocompromised 
hosts  involving  more  tissues,  but  these  cases  are 
extremely rare.
4,5 Therefore, the present review focuses 
only  on  the  zygomycotic  infections  caused  by 
mucorales.
The most important risk factors for mucormycosis 
include  prolonged  neutropenia,  diabetic  ketoacidosis, 
iron  overload  and  major  trauma.  Other  important 
predisposing  factors  of  mucormycosis  include 
prolonged  use  of  corticosteroids,  illicit  intravenous 
drug  use,  neonatal  prematurity,  malnourishment  and 
broad-spectrum  antimicrobial  agents,  as  well  as 
antifungal agents with no activity against zygomycetes, 
such  as  voriconazole  and  caspofungin.
6,7 The  same 
may also be true for the other echinocandins, but data 
are  lacking  as  they  are  not  as  widely  used  as 
caspofungin.  Risk  factors,  mechanisms  leading  to 
mucormycosis  and  clinical  presentation  forms  are 
illustrated in Table 1. 
The  recent  years,  mucormycosis  incidence  is 
seemingly  increasing,  particularly  in  patients  with
haematological  malignancies  or  haematopoieticMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2.   Percentages of mucormycosis cases according to underlying conditions. Data from 7 studies.
Underlying 
conditions
Roden et al. 
[6]
N=929
France
Bitar et al. 
[12]
1997-2006
N=531
Italy
Pagano et al. 
[13]
2004-2007
N=60
Belgium
Saegeman et 
al. [14]
2000-2009
N=31
FUNGISCO
PE
Rüping et al. 
[15]
2006-2009
N=41
ECMM/ISHAM
Registry
Skiada et al. [16]
2005-2010
N=230*
India
Chakrabarti 
et al. [17]
2000-2004
N=178
Haematol. 21 17.3 61.7 77 63.4 55 1.1
Diabetes 
Mellitus
36 16.2 18 6.4 17.1 17 73.6
SO Ca/T 7 7.1 1.7 13 9.8 9 0.6
DFO 6 1
HIV 2 4.9 1.7 3 2
AI/cortico 1 3.3 7
Trauma/no 
underlying 
disease
19 54.4 40 13 20 19.1
*Results from the 1
st ECMM study (ECMM/ISHAM Working group for a global registry for zygomycosis). Nineteen patients (8%) had more 
than one underlying disease, so the total is more than 100%. 
N=number  of  cases, Haematol.=haematologic  malignancies,  myelodysplastic  syndrome,  aplastic  anemia,  haematopoietic  stem  cell 
transplantation  (HSCT), SO  Ca/T=solid  organ  cancer/transplantation, DFO=deferoxamine  therapy, AI/cortico=autoimmune 
diseases/corticosteroid therapy.
stem  cell  transplantation,  at  least  in  western 
countries.
8,9,10 However,  accurate  estimation  of  the 
incidence is a challenge.  Data from a global registry 
are not available yet and moreover there are difficulties 
in  collecting  well  defined  denominator  data.  Much 
information  has  been  derived  from  the  first  most 
comprehensive study by Roden et al. 2005,
6 in which 
all  data  on  zygomycosis  recorded  in  the  English 
language literature ever since the first report by Platauf 
in  1885,
11 were  analyzed.  More  recent  data  from 
individual  countries  and  institutions  have  also  been 
reported
12-17and percentages of clinical cases according 
to underlying condition are presented in Table2.
Underlying Conditions
Diabetes  – Ketoacidosis: Diabetes  mellitus  as  a 
predisposing factor has been reported in 36–88% of all 
mucormycosis cases.
6,18-20 More  susceptible  are 
patients with uncontrolled hyperglycemia, particularly 
those with ketoacidosis.
21,22,23 Mucormycosis can also 
be  observed  in  metabolically  controlled  diabetic 
patients
24 and  was  found  to  be  the  first  clinical
manifestation  of  some  patients  with undiagnosed 
diabetes  mellitus.
25 Type  1,  type  2,  and  secondary 
diabetes mellitus have all been reported as risk factors 
in patients with mucormycosis.
26
In the normal host protection from mucormycosis is 
provided by macrophages. They prevent the initiation 
of infection by phagocytosis and oxidative killing of 
the  fungal  spores.  In  case  infection  is  established, 
neutrophils  are  activated  and  play  a  pivotal  role  in 
fungal killing. Activation happens in four phases: 
a) neutrophils are chemotactically attracted to the 
hyphae, 
b) they attach and 
c) spread on the hyphae and finally, 
d) using  their  oxidative  cytotoxic  system, 
neutrophils  damage  and  kill  the  fungal  elements 
without accompanying phagocytosis. 
In  diabetes,  each  of  the  four  phases  of  neutrophil 
activation is impaired.
27 Hyperglycemia per se does not 
seem  to  play  a  major  role  in  the  pathogenesis  of 
mucormycosis.  Chemotaxis, the  phagocytic  functions 
(adherence  and  spreading),  and  finally  the  oxidative 
burst  are  all  inhibited  in  the  ketoacidotic  state, 
essentially inducing functional neutropenia.
26-29
The  most  common  clinical  presentation  of 
mucormycosis  in  patients  with  diabetes  mellitus  is 
sinus disease (66%).
6 Diabetes mellitus was recognized 
as  a  major  risk  factor  for  developing  rhinocerebral 
mucormycosis  very  early  on.  The  publication  by 
Gregory  et  al.  in  1943  on  a  case  of  uncontrolled 
diabetes  was  the  first  to  describe  fulminant 
rhinocerebral mucormycosis.
30
Disease in diabetics can also present as pulmonary 
mucormycosis, a clinical presentation more common in 
neutropenic patients with malignancies or HSCT.
6
The  epidemiology in  diabetic  patients is  variable. 
Roden et al.
6 showed that diabetic patients represented 
36% of the 929 reported cases. They also reported a 
decreased incidence  of  mucormycosis  in  diabetic 
patients over time. This is in contrast to the increased 
prevalence  of  diabetes  in  the  world.
31 The  role  of 
statins,  used at  least  in  the  western  world, has  been 
speculated in an effort to explain this phenomenon.
32,33Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
In  France,  however,  a  population- based  study  of 
medical records of mucormycosis cases reported from 
1997  to  2006  showed  a  9%  yearly  increase  in  the 
annual  incidence  rate  in  the  diabetic  population.
12
Another retrospective study from the USA, reviewing 
cases  with  rhino-orbital-cerebral  mucormycosis  from 
two teaching tertiary-care hospitals revealed that 83% 
of cases were observed in diabetic patients and more 
importantly,  41%  of  them  had  no  known  history  of 
their condition.
34 A striking finding in this study was 
that  56%  of  the  patients  were  of  Hispanic  origin,  a 
much  larger  proportion  than  that  in  the  general 
population  (≈25%  expected  incidence  of  Hispanic 
ethnicity based on demographic characteristics at the 
study  hospitals).  Data  from  a  tertiary-care  centre  in 
India
35 were  also  overwhelming,  as  73.6%  of  cases 
were  observed  in  patients with  uncontrolled diabetes 
and in 42.7% of these cases diabetes was diagnosed for 
the  first  time.  These  findings  also  underline  the 
association between diabetes and socioeconomic status. 
Low income individuals have the tendency not to seek 
medical attention as healthcare is unaffordable to them, 
unless complications manifest. Almost 80% of type 2 
diabetes  deaths  occur  in  low- and  middle-income 
countries  (WHO  Fact  sheet:  Diabetes,  ref.
36).  With 
diabetes control programs in place, also many cases of 
mucormycosis could be prevented.
The  overall  mortality  of  diabetic  patients  with 
mucormycosis  who  undergo  treatment  is 
approximately  44%,  and  this  is  lower  compared  to 
other immunocompromising conditions.
6 This  can be 
explained by the relatively easy management of acute 
complications of diabetes compared to the management 
of  other  conditions.  This  percentage  can  be  further 
decreased with improved management.
37
Besides  diabetic  ketoacidosis,  chronic  metabolic 
acidosis  due  to  other  causes,  such  as  chronic  renal 
failure  with  uremia,
38 chronic  salicylate  poisoning,
39
and methylmalonicaciduria,
40 has also been reported as 
a risk factor for mucormycosis. 
Iron  overload  and  Deferoxamine (DFO) 
iron/aluminium  chelation  therapy:  Many 
microorganisms require iron to grow, and conditions of 
iron excess have been known to predispose to infection 
with certain bacteria.
41,42 Iron acquisition is a critical 
step  in  the  pathogenetic  mechanism  of 
mucormycosis.
43
Therapy  with  DFO, an iron  chelator used for  the 
treatment of iron and/or aluminum overload in dialysis 
patients, was found paradoxically to be a risk factor for 
angioinvasive  mucormycosis.
44,45 Although  the  first 
dialysis patient with mucormycosis, reported in 1979 
by Gluskin et al,
46 was not noted to be receiving DFO, 
subsequent  cases  of  mucormycosis  in  patients 
undergoing dialysis have been in those receiving DFO 
for  aluminum  or  iron  excess.
45 A  report  of  an 
international  registry
47 showed  that  78%  of  dialysis 
patients  with  mucormycosis  were  being  treated  with 
DFO.  In addition to patients with renal failure, patients 
with hematologic disorders, all of whom were treated 
with DFO, have been reported with mucormycosis.
45
Subsequent  research  showed  that  DFO  can  act  as  a 
siderophore  for  Mucorales:  DFO  forms  a  Fe-DFO 
complex  with  iron,  which then  binds  to  unidentified 
receptors on the surface of the zygomycetes. The iron 
is  subsequently liberated by the  fungus and is likely 
transported into the fungal cell by a high-affinity iron 
permease  (rFTR1).
43 The  increased  sensitivity  of 
dialysis  patients  to  DFO-related  mucormycosis  is 
explained  by  the  pharmacokinetic  changes  during 
uremia, which lead to a prolonged accumulation of Fe-
DFO after DFO administration.
48
Besides  DFO,  iron  overload  per  se,  either 
transfusional or due to dyserythropoiesis has also been 
recognized as a risk factor for mucormycosis.
49–51 In 
vitro and in vivo studies have shown that iron and DFO 
can  enhance  both  growth  and  pathogenicity  of 
Rhizopus  spp.  In  a  study  reviewing  a  series  of  five 
cases of invasive mucormycosis among 263 allogeneic 
bone  marrow  transplant  recipients,
51 the  association 
between severe iron overload and mucormycosis was 
demonstrated. The mean values of serum ferritin level, 
transferrin saturation, and number of transfused units 
of erythrocytes in the study group were significantly 
higher compared with the matched control group. 
Patients  with  diabetic  ketoacidosis  have  elevated 
levels of available serum iron, likely due to the release 
of iron from binding proteins in the presence of low 
pH. Iron is then internalized by the zygomycetes with 
the help of copper oxidase (Cu-oxidase) and the high 
affinity iron permease rFTR1. Therefore, the increased 
susceptibility of patients with diabetic ketoacidosis to 
mucormycosis  is  likely  due,  at  least  in  part,  to  an 
elevation  in  available  serum  iron  during  diabetic 
ketoacidosis following proton-mediated dissociation of 
iron from transferrin.
43
The most common presentation of mucormycosis in 
patients receiving DFO appears to be the disseminated 
form  (44%)  and  is  associated  with  high  mortality, 
reaching 80%.
6,47
In  contrast  to  DFO,  two  other  iron  chelators, 
deferiprone and deferasirox, do not supply iron to the 
fungus. This could be either because of their different 
structures and smaller size, rendering them inaccessible 
to fungal iron uptake systems, or because they share 
higher  affinity  constants  for  iron.
52 Deferiprone  and 
deferasirox  were  shown  to  have  fungicidal  activity
against  Zygomycetes  in  vitro.  Further,  both  iron 
chelators  were  shown  to  effectively  treat Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
mucormycosis  in  animal  models,  and  one  has  been 
successfully used as salvage therapy for a patient with 
rhinocerebral mucormycosis.
43
Solid  organ  malignancies  and  solid  organ 
transplantation (SOT): The incidence of mucormycosis 
in transplant recipients, including both hematopoietic 
stem cell transplant (HSCT) and solid organ transplant 
(SOT) patients has increased. Although global surveys 
of the incidence of mucormycosis are still lacking, data 
from  individual  countries  and  institutions  show  that 
mucormycosis  in  SOT  is  rare,  but  seems  to  be  a 
concern because of the high mortality rate. 
The  estimated  incidence  ranges  from  0.4  –
16%.
6,12,52,53 Data  from  the  Transplant Associated 
Infection Surveillance Network (TRANSNET) showed 
that  among  1063  solid  organ  transplant  recipients 
mucormycosis  represented  2%  of  invasive  fungal 
infections. Neutropenia predisposing to mucormycosis
6
was notably absent in SOT recipients as were acidosis 
with  or  without  hyperglycemia  and  use  of  DFO.  In 
contrast,  all  patients  were  receiving 
immunosuppression  and  the  overwhelming  majority 
was on corticosteroids. Furthermore, dissemination to 
distant organs occurred more frequently after rejection 
and its treatment.  
The  lung  seems  to  be  the  most  common  site  of 
infection  in  SOT  recipients  with  mucormycosis.
6,54
Dissemination occurred preferentially to cutaneous and 
soft  tissues,  and  not  the  brain.  Mycocladus 
(Lichtheimia) corymbifer as  causative  pathogen 
appeared  to  be  associated  with  a  higher  risk  for 
dissemination in SOT with pulmonary mucormycosis
in one study.
55
In a matched case-controlled study
54 SOT recipients 
with mucormycosis were prospectively studied. Renal 
failure, diabetes mellitus, and prior voriconazole and/or 
caspofungin  use  were  associated  with  a  higher  risk, 
whereas tacrolimus was associated with a lower risk of 
mucormycosis. Liver transplant recipients were more 
likely  to  have  disseminated  disease  and  developed 
mucormycosis  earlier  after  transplantation  than  did 
other SOT recipients (median, 0.8 versus 5.7 months).
HIV/AIDS - Intravenous drug abuse: Mucormycosis in 
HIV/AIDS patients is very rare. Antinori et al.
56 in a 
large retrospective study of 1630 autopsies of patients 
who died of AIDS during 1984 through 2002, found 
only 2 cases with mucormycosis. However, it can be 
the presenting opportunistic infection in AIDS.
57
Recently,  human  immunodeficiency  virus  (HIV) 
infection  has  been  recognized  as  a  risk  factor  for 
mucormycosis, but most cases in HIV-infected patients 
are also associated with intravenous drug abuse.
58,59,60,61
Cerebral  mucormycosis  with  basal  ganglia 
involvement is the usual clinical presentation in such 
cases, regardless of previous exposure to HIV.
62 The 
disease  may  develop  insidiously  or  may  progress 
rapidly with a fulminant course. 
Endocarditis as well as the rhinocerebral form can 
also occur. Merchant et al.
63 reported on a patient with 
rhinocerebral mucormycosis and also reviewed another 
6 cases reported in the literature. It is of note that 3 of 
them had hyperglycemia or diabetic ketoacidosis. 
Mucormycosis in the HIV+ can also present in the 
kidneys,  the  skin,  the  gastrointestinal  tract,  the 
respiratory tract, or may be disseminated.
64-75 How the 
fungus enters the body is not very clear. The fact that 
most of the infections occur at sites remote from the 
needle stick however, suggest that most probably this 
happens through spores contained in the illicit drugs.
1
Corticosteroids/Rheumatic  diseases:  Corticosteroid 
therapy is another primary risk factor that enhances a 
patient’s  susceptibility  to  mucormycosis  by  causing 
either  defects  in  macrophages  and  neutrophils or 
steroid-induced diabetes.
1
Corticosteroids  have  a  wide  range  of  complex 
immunosuppressive  effects,  mainly  by  affecting 
cellular immunity, and increase host susceptibility to 
invasive fungal infections.
76 The mechanism by which 
the corticosteroids enhance susceptibility to developing 
mucormycosis  is  probably  twofold.  First,  steroids 
suppress  the  normal  inflammatory  cell  response  that 
would otherwise occur, and second, they may induce a 
diabetic state.
77 In a recent study only 21% of patients 
with  corticosteroid  induced  diabetes  were  receiving 
medication for diabetes.
34
Of the few cases of mucormycosis in patients with 
lupus  erythematosus  (SLE)  reported  in  English 
language  literature
78-93 it  appears  that  disease  can 
present  with  any  clinical  form,  but  disseminated 
mucormycosis is usual in this group of patients. Mok et 
al.
78 reviewed  all  SLE  cases  published  from  1970 
through  2002  and  reported  a  very  high  overall 
mortality  of  mucormycosis  (88%).  Additional 
predisposing  factors  for  opportunistic  infection 
included  hypocomplementemia,  nephrotic  syndrome, 
uremia,  leukopenia,  and  diabetes  mellitus.  The 
diagnosis often was made only at autopsy (63%). The 
cutaneous  form  appeared  to  have  the  best  prognosis 
with combined medical and surgical treatment.
78
Mucormycosis in  other  autoimmune  diseases  are 
scarce,  but  in  cases  such  as  in  Wegener’s 
granulomatosis  it  may  mimic  disease  relapse  and 
remain underdiagnosed.
94
No underlying disease: A considerable proportion of 
patients with mucormycosis have no apparent immune 
deficiency.
6 These  patients  have  usually  primary Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
mucormycosis  of  the  skin  associated  with  burns, 
trauma,  insect  bites,  tattooing  and  also  complicating 
surgical wounds and catheter insertion sites. Recently, 
Skiada and Petrikkos reviewed 67 cases of cutaneous 
mucormycosis  in  English  language  literature,  from 
2004 -2008.
95 Most of the patients had an underlying 
immunocompromising condition such as haematologic 
malignancy,  diabetes,  or  solid  organ  transplantation, 
but  the  immunocompetent  represented  a  large 
proportion (40%). 
Infection usually occurs through direct inoculation. 
It  can  be  very  invasive  locally,  penetrating  the 
cutaneous and subcutaneous tissues into the adjacent 
fat, muscle, fascia and bone. In rare cases it can even 
disseminate  to  deep  organs.  Road  traffic  accidents, 
crush  injuries, but  also minor traumas such as those 
caused  by  plant  thorns  or  insect  bites,  can  lead  to 
traumatic  implantation  of  contaminated  soil  and 
subsequent  mucormycosis.  Major  burn  injury  is 
another  well  described  cause  of  cutaneous 
mucormycosis.  An  increased  risk  for  developing 
mucormycosis in burn patients is the development of a 
condition  called  “burned  stressed  pseudodiabetes”, 
which is marked by hyperglycemia and glycosuria.
96,97
In  a  new  PubMed  search  from  2008  - 2010,  we 
found 27 additional cases of cutaneous mucormycosis 
occurring in non immunocompromised hosts.
98-110 Risk 
factors  in  these  cases  included  soil  contaminated 
wounds, insect bites, burns, but the majority of cases 
(N=12)  were  iatrogenic,  either  after  surgery  or  at 
injection sites. Infections with Mucorales occurring in 
nosocomial settings have been repeatedly reported and 
have even caused small hospital outbreaks in the USA, 
the UK and in Europe.
111 Sources of infection included 
contaminated bandages, Elastopad adhesive dressings, 
wooden  tongue  depressors  and  non-sterile  karaya 
ostomy bags.
The  clinical  presentation  is  variable.  The  clinical 
signs initially are non specific, consisting of erythema 
and  induration.  Eventually  the  lesions  may  form 
blisters, pustules, or necrotic ulcerations. Cotton wool-
like material may also be observed on the margins of 
the  wound.  The  lesions  may  mimic  pyoderma 
gangrenosum,  bacterial  synergistic  gangrene  or 
infections  produced  by  Pseudomonas,  Aspergillus, 
Histoplasma etc. Biopsy specimens for histology and 
cultures are necessary to establish diagnosis. 
Strains  involved  are  usually  Rhizopus spp.  (the 
majority),  Lichtheimia  corymbifera (syn.  Absidia, 
Mycocladus),  Apohysomyces  elegans,  Mucor  spp., 
Cunninghamella  bertholetiae and  Saksenaea 
vasiformis. In the cases reported after 2008 the cultured 
species were R. arrhizus in 3 cases,
99,101 Lichtheimia 
spp.in 5,
98,100,107,109 A. elegans in 4,
98 S.  vasiformis in 
3,
98,102,110 and    Rhizomucor  variabilis  in  7.
103-104 The 
later,  a  non-thermophile  species  of  the  genus 
Rhizomucor, in contrast to other mucorales can cause 
large but slowly progressing opportunistic infections of 
the skin in immune-competent individuals. These fungi 
seem to have an increasing incidence in farmers from 
China.
The  prognosis  of  mucormycosis in  the 
immunocompetent is better than that in other patient 
groups  but  mortality  remains  high  depending  on  the 
site,  extension  of  infection  and  time  of  initiation  of 
antifungal therapy. Iatrogenic cutaneous mucormycosis 
could  easily  be  prevented  with  proper  preoperative 
preparation and postoperative dressing of the surgical 
sites.
Diagnosis:  The clinical  diagnosis  of  mucormycosis
among  non  haematological  immunocompromised 
patients  is  notoriously  difficult  because  of  the 
similarity with aspergillosis or other mycoses caused 
by filamentous fungi. Diagnosis is usually delayed, as   
the majority of the physicians are not so much familiar 
with the disease. The leading signs and symptoms of 
mucormycosis are presented in Table 3.
When  clinical  presentation  may  suggest 
mucormycosis,  imaging  techniques  are  helpful,  but 
cultures  and  histopathology  are  required  for 
confirmation.
In  case  of  rhinocerebral  involvement,  CT  and 
particularly  MRI  are  helpful  in  enabling  an  early 
detection  of  orbital,  sinus,  meningeal,  bone,  and 
cerebral  lesions  as  well  as  intracranial  vascular 
occlusion  even  before  clinical  signs  develop. In 
pulmonary mucormycosis, lung biopsies (endoscopic, 
CT-guided  or  surgical)  should  be  performed, 
depending on the radiological findings obtained by CT 
scans.  CT guided percutaneous lung biopsy has been 
found  highly  efficient  to  early  differentiate 
aspergillosis  from  mucormycosis  in  haematological 
patients. Whatever the initial clinical site involved, a 
sinus and chest CT are mandatory in addition to brain 
imaging. This is of major importance for the indicated 
therapeutic approach.
112
The  laboratory  diagnosis  of  mucormycosis is 
challenging  and  requires  expertise  and  proper 
sampling.  Proper  clinical  samples  include  scrapings 
and  aspirates  from  sinuses,  nasal  discharges,  BAL, 
needle biopsies from pulmonary lesions, skin scrapings 
from  cutaneous  lesions  and  biopsy  tissues.  
Zygomycetes are almost never isolated from blood and 
very  rarely  isolated  from  cultures  of  cerebrospinal 
fluid,  sputum,  urine  or  faeces,  or  swabs  of  infected 
areas.
113
The significance of the isolates grown in cultures 
may be doubtful, especially when grown from samples 
of non sterile sites, as they are commonly encounteredMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 3. Clinical forms and relevant signs and symptoms
Clinical forms Symptoms and clinical manifestations
Rhinocerebral, rhino-orbito-cerebral
Facial pain, headache, lethargy, loss of vision. Brownish, blood 
stained nasal discharge, black eschar on palate, chemosis, 
periorbital cellulitis, ophthalmoplegia, ptosis, proptosis, 
dysfunction of cranial nerves.
Pulmonary  Nonspecific:
Chest pain, dyspnoea, haemoptysis
Cutaneous Painful lesions, resemble ecthyma gangrenosum, cotton-like 
growth – “hairy pus”, necrotizing fasciitis.
Gastrointestinal Depend on site involved, non specific:
Abdominal pain, diarrhea, haematemesis, melena.
Disseminated
Most frequent clinical syndromes:
Pneumonia, stroke, subarachnoid haemorrhage, brain abscess, 
cellulitis or gangrene.
Focal (can affect any organ)
Protean manifestations according to involved organ:
Endocarditis, mediastinitis, peritonitis, osteomyelitis, 
pyelonephritis, otitis external, corneal infection
as  contaminants.  Histopathologic  evidence  of  fungal 
invasion  of  tissue  is  required  to  confirm  clinical  or 
radiological diagnosis and/or reliability of culture. 
The  direct  microscopic  examination  of  biopsy 
material  in  10%-20%  KOH  and/or  calcofluor-white 
wet  mount  shows  characteristic  broad  (6–15  μm  in 
diameter),  thin  walled,  mostly  aseptate,  ribbon-like 
hyaline hyphae with almost right –angle branching at 
irregular intervals. In tissue, Zygomycetes hyphae can 
be distinguished from the regularly septated hyphae of 
more common opportunistic molds such as Aspergillus 
spp.    Histopathologic  sections  occasionally  show 
folded, twisted, and compressed hyphae, which may be 
mistaken  for  septated  hyphae.  Sporangia,  the 
reproductive hyphal structures that contain spores, are 
seen  rarely  in  tissue  in  patients  infected  with 
zygomycetes.  These  hyphae  are  poorly  stained  with 
PAS and Gram stains but are very well seen by H&E, 
GMS,  or  Periodic-acid  Schiff stain.  Hyphae  may  be 
observed  within  necrotic  tissue  and  signs  of 
angioinvasion and infarction; neutrophilic infiltrates or 
granuloma formation may be present in patients who 
are  not  granulocytopenic  or  with  more  chronic 
infection, respectively.
114
Identification  of  zygomycetes  at  the  genus  and 
species  levels  requires  culture  studies,  because  all 
members of this group are morphologically similar in 
tissue.  Poor  recovery  of  Zygomycetes  may  reflect 
limited septation of the hyphae, making the fungi more 
liable  to  damage  resulting  from  tissue  excessive 
grinding. Samples should be kept at room temperature 
until  culture  plating, as  these  fungi  may not  survive 
refrigerator  temperatures,  and  excessive  grinding 
should  be  avoided.  The  zygomycetes  can  be  easily 
grown  on  conventional  media  like  SDA  with 
antibiotics,  at  temperatures  25
o  C  to 37
oC,  without 
cycloheximide as this substance is inhibitory to most of 
them except A. elegans. If all other media fail, sterile 
bread without preservatives in a test tube may recover 
zygomycetes from clinical samples, since these fungi 
are  commonly  associated  with  bread.
115 The  rapidly 
growing  mycelia  are  described  as  fibrous  or  cotton-
candy. 
There  are  no  reliable  serologic  or  skin  tests  for 
mucormycosis and the recently introduced antigen tests 
for  Aspergillus  (galactomannan)  and  other  fungal 
species  (b-D-glucan)  do  not  detect  Zygomycetes
because of the limited amount of galactomannan and 
glucan in their cell walls.
116
When cultures are negative, molecular identification 
of  zygomycetes  from  fresh  frozen  or  paraffin 
embedded  tissue  can  help  to  confirm  diagnosis  and 
identify  the  fungus  to  the  genus  and  species  level. 
Different techniques have been reported: DNA probes 
targeting the ribosomal 18S subunit, ITS1 sequencing 
after PCR with pan-fungal primers, 18S-targeted semi-
nested PCR and real-time PCR targeting cytochrome b 
gene.
117-122 The identification to the species level of a 
strain  isolated  in  culture  and  the  identification  of  a 
zygomycete in tissue by PCR make the diagnosis much 
easier.  However, at  present,  there is  no  standardized 
method  available.  Nevertheless,  problems  remain, 
since cultures are positive in only 50% of cases
6 and 
tissue for examination is not always available.
Sequencing  of  PCR  products  leads  to  a 
presumptive identification of the Zygomycetes, which 
provides some guidance in selecting antifungal therapy 
that  would  not  have  been  available  using 
histopathology alone. Molecular typing is most useful 
for  characterizing  zygomycete  epidemiology  in  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
setting of a cluster of nosocomial cases, outbreaks, or 
pseudo-outbreaks, in order to rule out clonal spread or 
a common infecting source.
Treatment:  The  prognosis  of  patients  with 
zygomycosis  due  to  Mucorales  without  treatment  is 
very  poor  approaching  100%,  depending  on  the 
underlying  condition  and  form  of  mucormycosis.
123
Given  the  rapid  development  of  the  disease,  early 
diagnosis  and immediate  initiation  of treatment is 
critical for a favourable outcome.
124
The  therapeutic  approach  to  mucormycosis  is 
multimodal,  with  an  equally  important  three-point 
strategy  that  includes  (a)  antifungal  therapy,  (b) 
surgical  debridement and  (c)  correction  of  the 
underlying  condition  predisposing  the  patient  to  the 
disease. Moreover, management of co-morbid factors 
and adjunctive treatments may improve host response.
Because  of  the  relative  rarity  of  mucormycosis, 
prospective, comparative studies  of antifungal agents 
and strategies have not been conducted. Therefore, the 
management of mucormycosis is so far based on the 
results of case series and case reports, animal model 
studies and in vitro susceptibility data.
The most frequently used antifungal agents to treat 
mucormycosis are listed in Table 4. 
Amphotericin  B  has  the  most  significant  in-vitro 
activity against Zygomycetes and has been successfully 
used  to  treat  mucormycosis  for  many  years. 
Amphotericin  B  deoxycholate  (d-AmB)  is  the  only 
antifungal  agent  that  has  been  approved  by  the  US 
Food and Drug Administration for primary treatment 
of  mucormycosis.  However,  this  formulation  has 
significant  toxicity.  The  newer  lipid  formulations  of 
amphotericin B that include liposomal AmB (L-AmB), 
AmB  lipid  complex  (ABLC),  and  AmB  colloidal 
dispersion  (ABCD)  are  less  nephrotoxic  and  have 
almost  completely  replaced  amphotericin  B 
deoxycholate in the recent years. It seems reasonable to 
recommend  either  L-AmB  or  ABLC  as  first-line 
treatment  for  mucormycosis.
125-128 The  optimal  daily 
dose,  as  well  as  the  length  of  treatment,  are  both 
undefined yet. Starting dosages of 5–7.5 mg/kg/day for 
L-AMB  and  of  5mg/kg/day  for  ABLC,  respectively, 
are commonly used for adults and children.
129
Of the azoles only posaconazole has in vitro activity 
against Zygomycetes and has been shown to be active 
as salvage therapy.
130,131 Some physicians are using the 
combination of posaconazole with amphotericin B, but 
the efficiency of this approach has not been proven in 
clinical trials. 
Zygomycetes  are  resistant  to  caspofungin  and  5-
flucytosine in vitro.
132,133 Itraconazole may have some 
activity  against  certain  strains  of  Rhizomucor  and 
Lichtheimia
134 and  could  be  an  option  especially  in 
cases  of  cutaneous infection.  However, despite  rare 
case  reports,
135-138 data  are  insufficient to  support  its 
use  as  monotherapy  of  mucormycosis  in  clinical 
practice.
Table  4. Most  frequently  used  antifungal  agents  to  treat 
mucormycosis and entomophthoramycosis (adapted from ref. 123)
Mucormycosis
Amphotericin B deoxycholate (Fungizone®) 
Amphotericin  B  cholesterol  sulfate  complex  (Amphotec®, 
Amphocil®) 
Liposomal amphotericin B (AmBisome®) 
Amphotericin B lipid complex (Abelcet®)
Posaconazole (Naxofil®, as salvage therapy) 
Entomophthoramycosis
Potassium iodide 
Itraconazole 
Ketoconazole 
Miconazole 
There  is  some  evidence  that  combination  of 
amphotericin B with caspofungin  may be active, but 
these results are preliminary.
139
Certain  Mucorales  species  have  however  variable 
susceptibilities  to  amphotericin,  with  MICs  ranging 
from  <1  to  100  μg/ml  and  treatment  may  be 
unsuccessful.  Moreover, the  drug  may  not  reach  the 
target because of tissue infarction and thrombosis.
140 In 
order  to  increase  oxygen  concentration  in  tissues 
hyperbaric oxygen has been used as adjunctive therapy 
in limited studies, but evidence is insufficient to define 
the efficacy of this expensive intervention.
141
Another option for the treatment of mucormycosis 
is the adjunctive use of iron-chelators deferasirox and 
deferiprone.  A  clinical  trial  is  currently  underway, 
testing the combination of deferasirox with liposomal 
amphotericin B.
Granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage  colony-stimulating  factor 
(GM-CSF), G-CSF and GM-CSF are routinely given to 
neutropenic  patients  with  mucormycosis  or  another 
invasive fungal disease. These two cytokines have also 
be used in a limited number of cases of mucormycosis 
in  non-neutropenic  patients  as  adjunctive  treatment 
with favorable outcomes.
142,143
Treating  a  patient’s  underlying  medical  condition 
and  reducing  immunosuppression  are  essential  to 
therapy. Rapid correction of metabolic abnormalities is 
mandatory  in  uncontrolled  diabetes.  Corticosteroids
should  be  discontinued,  if  feasible,  and  other 
immunosuppressive drugs should be tapered as much 
as possible. 
Diabetics  may  have  a  more  favourable  outcome 
than non-diabetics. An overall survival rate of 60-77% 
for  rhino-orbito-cerebral  mucormycosis  has  been 
reported  in  diabetics,  versus  20-34%  in  non-
diabetics.
144,145 Combined surgical and medical therapy Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
leads to reduced mortality rates compared to medical 
treatment alone.
6,146
Despite  the  progress  in  the  treatment  of 
mucormycosis,  many problems  are  yet  unsolved and 
the mortality of the disease is still high. 
Conclusions: Depending on the underlying condition 
of immunocompromised non- haematological patients, 
mucormycosis can manifest in various clinical forms: 
mostly  as  rhino-orbital  or  rhino-cerebral  in  diabetes 
patients,  pulmonary  infection  in  patients  with 
malignancy  or  solid  organ  transplantation, 
disseminated  infection  in  iron  overloaded  or 
deferoxamine treated patients, cerebral - with no sinus 
involvement - in ID users, gastrointestinal in premature 
infants,  and  cutaneous after  direct  inoculation  in  the 
immunocompetent. 
Although  there  are  many  unresolved  issues 
concerning the epidemiology, diagnosis and treatment 
of  mucormycosis,  advances  have  been  made. 
Knowledge  of  the  differential  patterns  of  clinical 
presentation can raise the suspicion index for these rare 
but  highly  lethal  infections.  This  is  very  important 
since prompt and appropriate management can reduce 
mortality and morbidity considerably.
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